Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Eli Lilly & Co. pages available for free this week:
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Eli Lilly & Co. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Long-term Activity Ratios (Summary)
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The analysis of investment activity ratios from March 2022 through March 2026 reveals a general trend of stabilization following an initial period of efficiency contraction. While the utilization of total assets remained relatively consistent over the long term, there are distinct shifts in how fixed assets and equity were leveraged to generate revenue.
- Net Fixed Asset Turnover
- A downward trend is observed during the first half of the period, with the ratio declining from a peak of 3.22 in March 2022 to a low of 2.53 by September 2024. This suggests a period where the growth of fixed assets outpaced the growth of net sales. However, the ratio stabilized in the latter half of the period, oscillating between 2.59 and 2.72, indicating a realignment between capital investment in fixed assets and revenue generation.
- Total Asset Turnover
- Total asset efficiency remained remarkably stable, fluctuating within a narrow band between 0.52 and 0.62. A slight dip occurred between December 2022 and June 2023, reaching a minimum of 0.52. Following this trough, the ratio showed a gradual recovery, returning to its initial level of 0.62 by March 2026. This indicates a consistent ability to generate revenue relative to the total asset base despite intermittent fluctuations.
- Equity Turnover
- The equity turnover ratio exhibited the highest level of volatility among the measured metrics. After an initial peak of 3.40 in June 2022, the ratio experienced significant fluctuations, including a drop to 2.47 in March 2023 and a subsequent recovery to 3.17 by December 2024. A pronounced downward trend emerged in the final year, with the ratio falling steadily to 2.32 by March 2026. This contraction suggests an increase in shareholder equity that has outpaced the growth in sales during the final phase of the analyzed period.
Net Fixed Asset Turnover
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Revenue | |||||||||||||||||||||||
| Property and equipment, net | |||||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||||
| Net fixed asset turnover1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Net Fixed Asset Turnover, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Net fixed asset turnover
= (RevenueQ1 2026
+ RevenueQ4 2025
+ RevenueQ3 2025
+ RevenueQ2 2025)
÷ Property and equipment, net
= ( + + + )
÷ =
2 Click competitor name to see calculations.
An analysis of the long-term activity ratios reveals a period of aggressive capacity expansion coupled with significant revenue acceleration. The data indicates a strategic shift where massive capital investments were front-loaded, followed by a period of scaling operational output to optimize asset utilization.
- Revenue Growth Trends
- Revenue exhibits a strong upward trajectory, rising from 7,810 million USD in March 2022 to 19,799 million USD by March 2026. The growth acceleration becomes most prominent starting in June 2024, with quarterly revenues consistently exceeding 11,000 million USD, reflecting a substantial increase in market demand or product scaling.
- Fixed Asset Investment
- Net property and equipment increased consistently throughout the period, growing from 9,103 million USD in March 2022 to 26,540 million USD by March 2026. This nearly threefold increase in the net asset base confirms a period of intensive capital expenditure aimed at expanding production capabilities.
- Net Fixed Asset Turnover Dynamics
- The net fixed asset turnover ratio experienced an initial decline, dropping from 3.22 in March 2022 to 2.62 by June 2023. This contraction is characteristic of an investment phase where the growth in the asset base temporarily outpaces the growth in generated revenue. Following this decline, the ratio entered a stabilization phase, fluctuating narrowly between 2.53 and 2.72 for the remainder of the period. The final increase to 2.72 by March 2026 suggests that the newly acquired assets have reached a level of operational maturity, improving the efficiency with which the company generates sales from its fixed asset investments.
Total Asset Turnover
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Revenue | |||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||||
| Total asset turnover1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Total Asset Turnover, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Total asset turnover
= (RevenueQ1 2026
+ RevenueQ4 2025
+ RevenueQ3 2025
+ RevenueQ2 2025)
÷ Total assets
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of investment activity reveals a period of significant balance sheet expansion followed by a recovery in operational efficiency. While both revenue and total assets grew substantially between March 2022 and March 2026, the rate of asset accumulation initially outpaced revenue growth, leading to a temporary compression in the total asset turnover ratio before a return to previous efficiency levels.
- Revenue Trajectory
- Revenue exhibited a strong upward trend, increasing from 7,810 million USD in March 2022 to 19,799 million USD by March 2026. Growth remained relatively steady through 2023, followed by a sharp acceleration beginning in mid-2024, with quarterly revenues consistently exceeding 15,000 million USD by the second half of 2025.
- Asset Base Expansion
- Total assets grew aggressively over the analyzed period, rising from 46,919 million USD in March 2022 to 116,576 million USD by March 2026. A notable surge in asset acquisition is observed between December 2023 and June 2025, where the asset base expanded from approximately 64,000 million USD to over 100,000 million USD, suggesting significant capital investment in infrastructure or capacity.
- Total Asset Turnover Performance
- The total asset turnover ratio began at 0.62 in early 2022 and experienced a gradual decline to a low of 0.52 by March 2023. This downward trend indicates that assets were being added more quickly than the revenue they were intended to generate. The ratio remained suppressed, fluctuating between 0.52 and 0.57 for several quarters, reflecting a phase of heavy investment. However, a recovery is observed in the final quarters, with the ratio climbing back to 0.62 by March 2026.
- Operational Efficiency Correlation
- The correlation between the asset base and revenue suggests a strategic investment cycle. The initial drop in turnover indicates a period of "building" or capacity expansion. The subsequent rise in the turnover ratio in late 2025 and early 2026 confirms that the expanded asset base has begun to translate into higher revenue yields, effectively restoring the company's asset utilization efficiency to its 2022 levels despite a much larger operational scale.
Equity Turnover
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Revenue | |||||||||||||||||||||||
| Total Eli Lilly and Company shareholders’ equity | |||||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||||
| Equity turnover1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Equity Turnover, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Equity turnover
= (RevenueQ1 2026
+ RevenueQ4 2025
+ RevenueQ3 2025
+ RevenueQ2 2025)
÷ Total Eli Lilly and Company shareholders’ equity
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The financial trajectory from March 2022 through March 2026 is characterized by substantial growth in both top-line revenue and the total equity base, though the pace of these increases has varied, impacting the overall efficiency of equity utilization.
- Revenue Growth Trends
- Revenue exhibited a consistent upward trajectory over the analyzed period. Starting at 7,810 million US$ in March 2022, revenue climbed to 19,799 million US$ by March 2026. A period of accelerated growth is particularly evident beginning in June 2024, where quarterly figures surged from 11,303 million US$ to nearly 20 billion US$ by the end of the series, indicating strong market expansion or product success.
- Shareholders' Equity Expansion
- Total shareholders' equity grew from 9,331 million US$ in March 2022 to 31,198 million US$ in March 2026. While the growth was gradual between 2022 and 2024, a significant acceleration occurred between June 2025 and March 2026, where equity increased from 18,273 million US$ to 31,198 million US$, representing a rapid expansion of the company's capital base.
- Equity Turnover Performance
- The equity turnover ratio experienced volatility and an eventual decline. The ratio peaked early at 3.40 in June 2022, followed by a period of relative stability between 2.47 and 3.17 from March 2023 through December 2024. However, a sustained downward trend emerged in 2025, with the ratio falling from 3.11 in March 2024 to 2.32 by March 2026.
- Correlation Analysis
- The decline in equity turnover during the final quarters is attributed to the fact that shareholders' equity grew at a faster rate than revenue. While revenue increased approximately 2.5 times over the period, equity increased more than 3.3 times. This divergence suggests that the increase in the capital base has outpaced the generation of proportional sales, leading to a reduction in the efficiency of equity deployment in the most recent periods.